News & Opinions - Headlines | chemanager-online.com - Chemistry and Life Science

Nov. 27, 2019
News & OpinionsHeadlines
Generic Price-fixing Probe may See Progress
Israeli generics giant Teva Pharmaceuticals and other generic drugmakers have been discussing possible settlements with US federal prosecutors in a long-running price-fixing probe. After six months there are signs the talks may ...
Nov. 26, 2019
News & OpinionsHeadlines
Russian-Chinese Project Takes Shape on the Baltic
Plans for a mammoth Russian-Chinese ethane cracker and polyethylene complex are taking shape in the Russian Baltic seaport of Ust-Luga, near the Gulf of Finland and the starting point of the controversial North Stream 2 pipeline planned to ...
Nov. 26, 2019
News & OpinionsHeadlines
Merck & Co. Takes Calporta for $576 Million
US Merck & Co. has agreed to buy Calporta Therapeutics for up to $576 million, including an upfront sum and contingent milestone payments. ...
Nov. 26, 2019
News & OpinionsHeadlines
Ineos Pushes More European Recycling Projects
Ineos is pressing full speed ahead on plans for jumping on board the European circular economy train, which is gathering more and more steam. ...
Nov. 25, 2019
News & OpinionsHeadlines
Turkish Cargo Expanding Flight Network for Pharmaceutical Products
Turkish Airlines Chief Cargo Officer, Turhan Özen stated: "... we carry out the pharmaceutical transports from Atatürk and Istanbul Airports that have been certified by the global air cargo authorities and thus hold the IATA CEIV ...
Nov. 25, 2019
News & OpinionsHeadlines
BASF Kicks off Latest Chinese Project
BASF has broken ground for the first production facilities of its latest mega investment in Zhanjiang, Guangdong Province, China, expected to be worth as much as $10 billion altogether. The first plants will produce engineering plastics ...
Nov. 25, 2019
News & OpinionsHeadlines
Novartis to Acquire US Cholesterol Drug Specialist
Swiss drugmaker Novartis announced on Nov.
Nov. 22, 2019
News & OpinionsHeadlines
FTC Questions Sandoz-Aurobindo Deal Plans
Plans by Swiss drugmaker Novartis to sell $1 billion worth of assets belonging to its Sandoz generics subsidiary to India’s Aurobindo Pharma may run afoul of the US Federal Trade Commission (FTC). In any case, it looks assured that ...

1 2 345 6 7 8…

Register now!

The latest information directly via newsletter.

GIT Verlag